Navigation Links
AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results
Date:11/13/2008

All amounts are in U.S. dollars

QUEBEC CITY, Nov. 13 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), a global biopharmaceutical company focused on endocrinology and oncology, today reported financial and operating results for the third quarter ended September 30, 2008.

Third Quarter 2008 Highlights

- Appointment on September 1, 2008, of Juergen Engel, Ph.D. as President

and CEO of AEterna Zentaris, replacing Juergen Ernst who had been

acting as Interim President and CEO since April 2008. Mr. Ernst, the

former Chairman of the Company, was appointed Executive Chairman

effective September 1, 2008;

- Completion of patient recruitment for the second efficacy trial of the

Phase 3 program in benign prostatic hyperplasia (BPH) with lead

compound, cetrorelix;

- Start of second stage of recruitment for the Phase 2 trial in ovarian

cancer with AEZS-108. The trial is part of a Phase 2 program in

gynaecological cancers which will include up to 82 women;

- Signing of a license and cooperation agreement for the

commercialization of cetrorelix in BPH, with Handok Pharmaceuticals

Co., Ltd. (Handok) for the Korean market. Subsequent to quarter end,

signing of another agreement with Handok for the commercialization of

ozarelix in BPH for the Korean market; and

- Recovery of worldwide rights from Ardana plc (LSE: ARA) for the Growth

Hormone Secretagogue (GHS) compound, AEZS-130. Future development

options are currently being evaluated for the use of this compound in

growth hormone deficiencies.

Subsequent to Quarter-End

On November 11, 2008, AEterna Ze
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. AEterna Zentaris to Announce Third Quarter 2008 Financial and Operating Results on November 13, 2008
2. AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
3. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
4. AEterna Zentaris to Present at Upcoming Oppenheimer 19th Annual Healthcare Conference
5. AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price
6. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
7. AEterna Zentaris to Present at BioContact Quebec on October 2, 2008
8. AEterna Zentaris to Present at Upcoming CIBC World Markets 7th Annual Eastern Investor Conference
9. AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results
10. AEterna Zentaris Announces Appointment of Prof. Jurgen Engel, Ph.D. as New President and CEO
11. AEterna Zentaris to Announce Second Quarter 2008 Financial and Operating Results on August 12, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Calif. , July 25, 2014 Amgen ... of Directors today declared a $0.61 per share dividend ... be paid on Sept. 5, 2014, to all stockholders ... Aug. 14, 2014.  About Amgen Amgen ... patients suffering from serious illnesses by discovering, developing, manufacturing ...
(Date:7/25/2014)... According to a new market report published ... Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 ... at USD 161,056.5 million in 2014 and is expected ... to 2020, to reach an estimated value of USD ... is witnessing a significant growth due to the increasing ...
(Date:7/25/2014)... 25, 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: ... the development and commercialization of a once-daily, oral therapy ... today announced financial results for the period ended June ... , Reported cash and cash equivalents totaling $37.4 ... December 31, 2013.  , Reported a net loss ...
(Date:7/24/2014)... - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) ... long-term, randomized, active control Phase 3 study of Zerenex ... binder, for the treatment of hyperphosphatemia in patients with ... (PhosphatE binding and iRon delivery with FErric CiTrate in ... of the American Society of Nephrology ( JASN ...
Breaking Biology Technology:Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4
... May 11 /PRNewswire-Asia-FirstCall/ -- China,Baicaotang Medicine Ltd. (OTC Bulletin Board: ... in the, Guangxi Province of China announced today that ... the,Company. , , , ... Mr. Tang Hui Tian , Chairman and CEO of CBT, ...
... of more affordable drugs, vaccines and diagnostics that would ... from a growing number of collaborations between biotech firms ... published Mon. May 10 in the UK journal ... countries, together with colleagues at Canada,s McLaughlin-Rotman Centre for ...
... May 10 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical,Inc. ("China Sky ... pharmaceutical company producing over-the-counter drugs in, the People,s Republic of China , ... of $10.1 million for the first quarter,ended March 31, ... ...
Cached Biology Technology:Harbinger Research Initiates Coverage on China Baicaotang Medicine, Ltd. 2Harbinger Research Initiates Coverage on China Baicaotang Medicine, Ltd. 3Cheaper drugs, vaccines forecast as collaborations grow between developing countries' biotech firms 2Cheaper drugs, vaccines forecast as collaborations grow between developing countries' biotech firms 3Cheaper drugs, vaccines forecast as collaborations grow between developing countries' biotech firms 4Cheaper drugs, vaccines forecast as collaborations grow between developing countries' biotech firms 5Cheaper drugs, vaccines forecast as collaborations grow between developing countries' biotech firms 6Cheaper drugs, vaccines forecast as collaborations grow between developing countries' biotech firms 7China Sky One Medical Announces Preliminary First Quarter 2010 Results; Reschedules Earnings Conference Call 2China Sky One Medical Announces Preliminary First Quarter 2010 Results; Reschedules Earnings Conference Call 3China Sky One Medical Announces Preliminary First Quarter 2010 Results; Reschedules Earnings Conference Call 4China Sky One Medical Announces Preliminary First Quarter 2010 Results; Reschedules Earnings Conference Call 5China Sky One Medical Announces Preliminary First Quarter 2010 Results; Reschedules Earnings Conference Call 6
(Date:7/25/2014)... 24, 2014)The link between autism and disrupted brain ... of the disease, and is largely unknown. However, ... Research Initiative (SFARI), George Washington University (GW) researcher ... truly integrative and in-depth answers to these key ... , LaMantia, professor of pharmacology and physiology at ...
(Date:7/25/2014)... Birla, associate professor of biomedical engineering at the ... on tissue engineering and artificial organ development., "Introduction ... comprehensive guide to entering into the field of ... professor of biomedical engineering at UH, served as ... that while there are other published books on ...
(Date:7/25/2014)... a pleiotropic factor characterized by the existence of ... that confer to the protein deeply different characteristics. ... myelination occurring during development and the different phases ... degeneration, axon regrowth, remyelination and target reinnervation, Researchers ... that the soluble NRG1 upregulation observed in Schwann ...
Breaking Biology News(10 mins):GW researcher receives grant to answer the how and why of autism during development 2University of Houston researcher publishes textbook on tissue engineering 2
... Capabilities for Use in a Wide,Range ... Vision Applications, VILNIUS, Lithuania, Sept. ... provider of high-precision biometric,and object identification ... 2.0 SDK universal object recognition technology ...
... always good to respond maximally when pathogens or disease ... balance immediate and future costs? This is the question ... Tony Williams asked when they examined how a simple ... life-span of individual zebra finches ( Taeniopygia guttata ), ...
... of stripy legs in a camera trap photo snapped in ... from the Wildlife Conservation Society. The legs belong to an ... Republic of Congo,s Virunga National Park, despite over a decade ... the first time this species has been captured on film ...
Cached Biology News:Neurotechnology Releases SentiSight 2.0 SDK Universal Object Recognition Technology 2Neurotechnology Releases SentiSight 2.0 SDK Universal Object Recognition Technology 3Individuals vary their immune response according to age, sex and the costs 2Photo reveals rare okapi survived poaching onslaught 2
... Imaging System, Professional Package Superior Protein ... Range: The ProXPRESS 2D Proteomic Imaging System ... for both proteomic and general life science ... enabling the use of all dyes in ...
... Corning single use spatulas have been ... samples. They are for those interested in ... reusable spatulas. Each spatula is individually packaged, ... CLS number is a new product number, ...
... digital valve, just 8 mm in width. ... in a single glass-reinforced, PBT (Polybutylene Terephthalate) molded ... width. , Meets a range of pressure requirements ... Satisfies a 0.016 sccm leakage specification (0.2 sccm ...
... FilterMate is a compact, versatile system that ... 96- or 24-well microplates into a solid ... liquid scintillation and gamma counter. The FilterMate ... for applications such as cell proliferation, receptor ...
Biology Products: